(CIDRAP News) – The US Food and Drug Administration (FDA) yesterday approved the nation's first cell-based flu vaccine, a product from Novartis that uses technology that could help vaccinate more Americans in a pandemic but still has many of the same limitations of older egg-based flu vaccines.
(CIDRAP News) – Novartis's new cell-culture based influenza vaccine factory in North Carolina has begun making a prepandemic H5N1 flu vaccine and is ready to start producing vaccines for a real pandemic when needed, the company and federal health officials announced yesterday.
The facility in Holly Springs, N.C., billed as the first of its kind in the United States, was dedicated yesterday after a long testing process.
(CIDRAP News) – The era of cell-based influenza vaccine production in the United States seemed to move closer today as Novartis unveiled its new, nearly billion-dollar manufacturing plant in Holly Springs, N.C., but onshore production and marketing of cell-based vaccines remains a few years away.
(CIDRAP News) – The US government has awarded Novartis a $487 million contract to help build a plant in North Carolina that the company says will be capable of producing 150 million doses of cell-based pandemic influenza vaccine within 6 months after the start of a pandemic.
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) – A committee that reviews medical product applications for the European Union (EU) yesterday recommended approval of a cell-based seasonal influenza vaccine made by Novartis, improving the company's chance of becoming the first to market a flu vaccine grown in cell culture instead of in eggs.
(CIDRAP News) Novartis, the Swiss-based drug manufacturer, today announced plans to build what it says will be the first US plant to make cell-culture-based influenza vaccines.
The facility will be built in Holly Springs, N.C., at a total cost of about $600 million, the company said in a news release. It will be able to produce about 50 million doses of seasonal trivalent (three-strain) flu vaccine annually.
(CIDRAP News) In an effort to modernize vaccine production while preparing for an influenza pandemic, the US government today awarded five contracts totaling more than $1 billion to develop cell-based technologies for making flu vaccines.